PARMAR KUSH
SEC CIK 1664281 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| TRDA | Entrada Therapeutics, Inc. | Dir, 10% | 2.69M | $5.00M | $4.71M | 7 | 2021-11-02 | 2026-08-06 |
| SKYE | Skye Bioscience, Inc. | 10% | 8.39M | $4.50M | — | 1 | 2024-03-13 | 2024-03-13 |
| RLYB | Rallybio Corp | Dir, 10% | 2.38M | $8.00M | $6.74M | 6 | 2021-07-28 | 2023-03-07 |
| VOR | Vor Biopharma Inc. | Dir, 10% | 1.77M | — | $5.06M | 1 | 2021-11-16 | 2021-11-16 |
Most active insiders at TRDA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | PARMAR KUSH | Dir, 10% | — | $3.65M |
| 2 | MPM BIOVENTURES 2018, L.P. | 10% | — | $3.60M |
| 3 | MPM BioVentures 2014, L.P. | 10% | — | $3.60M |
| 4 | 5AM Ventures V, L.P. | 10% | — | $3.00M |
| 5 | Baker Bros. Advisors (GP) LLC | 10% | $1.35M | — |
| 6 | WENTWORTH KORY JAMES | CFO | — | $433.6K |
| 7 | Dowden Nathan J | Pres, COO | — | $425.7K |
| 8 | Sethuraman Natarajan | Pres, Research, Develop | — | $398.8K |
| 9 | BAKER FELIX | 10% | $261.8K | — |
| 10 | Zeiher Bernhardt G | Dir | $29.3K | — |
Transactions 15
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2026-08-10 19:54 | 2026-08-06+ | TRDA | Entrada Therapeutics, Inc. | PARMAR KUSH | Dir | S - Sale | $6.95 | -155.3K | 2.69M | -5% | -$1.08M |
| MI | 2026-08-03 17:26 | 2026-07-30+ | TRDA | Entrada Therapeutics, Inc. | PARMAR KUSH | Dir, 10% | S - Sale | $6.93 | -116.5K | 2.85M | -4% | -$807.0K |
| I | 2025-11-18 | 2025-11-14 | TRDA | Entrada Therapeutics, Inc. | PARMAR KUSH | Dir, 10% | S - Sale | $8.80 | -200.0K | 2.96M | -6% | -$1.76M |
| MI | 2025-07-11 | 2025-07-09 | TRDA | Entrada Therapeutics, Inc. | PARMAR KUSH | Dir, 10% | S - Sale | $7.50 | -27.0K | 1.09M | -2% | -$202.5K |
| MI | 2025-07-01 | 2025-06-27+ | TRDA | Entrada Therapeutics, Inc. | PARMAR KUSH | Dir, 10% | S - Sale | $6.93 | -125.0K | 3.22M | -4% | -$866.5K |
| I | 2024-03-15 | 2024-03-13 | SKYE | Skye Bioscience, Inc. | PARMAR KUSH | 10% | P - Purchase | $10.00 | +450.0K | 8.39M | +6% | +$4.50M |
| I | 2023-03-09 | 2023-03-07 | RLYB | Rallybio Corp | PARMAR KUSH | Dir | S - Sale | $8.20 | -100.0K | 2.38M | -4% | -$820.0K |
| MI | 2022-06-07 | 2022-06-03 | RLYB | Rallybio Corp | PARMAR KUSH | Dir, 10% | S - Sale | $12.50 | -150.0K | 1.25M | -11% | -$1.88M |
| MI | 2022-05-25 | 2022-05-23 | RLYB | Rallybio Corp | PARMAR KUSH | Dir, 10% | S - Sale | $13.00 | -100.0K | 1.30M | -7% | -$1.30M |
| MI | 2022-02-10 | 2022-02-08 | RLYB | Rallybio Corp | PARMAR KUSH | Dir | S - Sale | $13.05 | -210.0K | 1.34M | -14% | -$2.74M |
| MI | 2021-11-18 | 2021-11-16 | VOR | Vor Biopharma Inc. | PARMAR KUSH | Dir, 10% | S - Sale | $15.30 | -330.7K | 1.77M | -16% | -$5.06M |
| DMI | 2021-11-05 | 2021-11-02 | TRDA | Entrada Therapeutics, Inc. | PARMAR KUSH | Dir, 10% | C - Cnv Deriv | — | +3.83M | 649.8K | New | — |
| DI | 2021-11-05 | 2021-11-02 | TRDA | Entrada Therapeutics, Inc. | PARMAR KUSH | Dir, 10% | P - Purchase | $20.00 | +250.0K | 1.13M | +28% | +$5.00M |
| DMI | 2021-08-04 | 2021-07-28 | RLYB | Rallybio Corp | PARMAR KUSH | Dir | J - Other | — | +3.58M | 790.7K | New | — |
| DI | 2021-08-04 | 2021-08-02 | RLYB | Rallybio Corp | PARMAR KUSH | Dir | P - Purchase | $13.00 | +615.4K | 1.41M | +78% | +$8.00M |
Purchase Sale Sale after option exercise All abbreviations